July 16, 2015
The whistleblower who alerted the government to Endo Pharmaceuticals Inc.'s off-label marketing of the pain-relief patch Lidoderm won 24 percent of a $140 million False Claims Act settlement Wednesday, with a Pennsylvania federal judge rejecting the government's argument she deserved only 19 percent.
June 24, 2014
A Pennsylvania federal court ruled Monday that only one of three whistleblowers can take a portion of Endo Pharmaceuticals Inc.'s $193 million settlement with the U.S. Department of Justice over the off-label marketing of the pain-relief patch Lidoderm, saying only the first to file suit is entitled to the award.